The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Inhibiting the Hedgehog Pathway in Patients with the Basal-Cell Nevus Syndrome
Open accessAbstract
BACKGROUND: Dysregulated hedgehog signaling is the pivotal molecular abnormality underlying basal-cell carcinomas. Vismodegib is a new orally administered hedgehog-pathway inhibitor that produces objective responses in locally advanced and metastatic basal-cell carcinomas. METHODS: We tested the anti-basal-cell carcinoma efficacy of vismodegib in a randomized, double-blind, placebo-controlled trial in patients with the basal-cell nevus syndrome at three clinical centers from September 2009 through January 2011. The primary end point was reduction in the incidence of new basal-cell carcinomas that were eligible for surgical resection (surgically eligible) with vismodegib versus placebo after 3 months; secondary end points included reduction in the size of existing basal-cell carcinomas. RESULTS: In 41 patients followed for a mean of 8 months (range, 1 to 15) after enrollment, the per-patient rate of new surgically eligible basal-cell carcinomas was lower with vismodegib than with placebo (2 vs. 29 cases per group per year, P<0.001), as was the size (percent change from baseline in the sum of the longest diameter) of existing clinically significant basal-cell carcinomas (-65% vs. -11%, P=0.003). In some patients, all basal-cell carcinomas clinically regressed. No tumors progressed during treatment with vismodegib. Patients receiving vismodegib routinely had grade 1 or 2 adverse events of loss of taste, muscle cramps, hair loss, and weight loss. Overall, 54% of patients (14 of 26) receiving vismodegib discontinued drug treatment owing to adverse events. At 1 month, vismodegib use had reduced the hedgehog target-gene expression by basal-cell carcinoma by 90% (P<0.001) and diminished tumor-cell proliferation, but apoptosis was not affected. No residual basal-cell carcinoma was detectable in 83% of biopsy samples taken from sites of clinically regressed basal-cell carcinomas. CONCLUSIONS: Vismodegib reduces the basal-cell carcinoma tumor burden and blocks growth of new basal-cell carcinomas in patients with the basal-cell nevus syndrome. The adverse events associated with treatment led to discontinuation in over half of treated patients. (Funded by Genentech and others; ClinicalTrials.gov number, NCT00957229.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2005) · Statistics for Biology and Health · doi:10.1007/0-387-27255-0_9 · Cited by 20,133
McCullagh, P., & Nelder, J. A. (1989) · doi:10.1007/978-1-4899-3242-6 · Cited by 16,836
Generalized Linear Models (2nd ed.).
Therneau, T. M., McCullagh, P., & Nelder, J. A. (1993) · Journal of the American Statistical Association · doi:10.2307/2290358 · Cited by 4,907
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Mutations of the Human Homolog of Drosophila patched in the Nevoid Basal Cell Carcinoma Syndrome
Hahn, H., Wicking, C., Zaphiropoulos, P. G., Gailani, M. R., Shanley, S., Chidambaram, A., Vorechovsky, I., Holmberg, E., Unden, A. B., Gillies, S., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81268-4 · Cited by 2,022
Human Homolog of patched , a Candidate Gene for the Basal Cell Nevus Syndrome
Johnson, R. L., Rothman, A. L., Xie, J., Goodrich, L. V., Bare, J. W., Bonifas, J. M., Quinn, A. G., Myers, R. M., Cox, D. R., Epstein, E. H., et al. (1996) · Science · doi:10.1126/science.272.5268.1668 · Cited by 1,857
Self-citationEfficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma
Sekulic, A., Migden, M. R., Oro, A. E., Dirix, L., Lewis, K. D., Hainsworth, J. D., Solomon, J. A., Yoo, S., Arron, S. T., Friedlander, P. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113713 · Cited by 1,464
Self-citationActivating Smoothened mutations in sporadic basal-cell carcinoma
Xie, J., Murone, M., Luoh, S.-M., Ryan, A., Gu, Q., Zhang, C., Bonifas, J. M., Lam, C.-W., Hynes, M., Goddard, A., et al. (1998) · Nature · doi:10.1038/34201 · Cited by 1,334
Self-citationInhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma
Von Hoff, D. D., LoRusso, P. M., Rudin, C. M., Reddy, J. C., Yauch, R. L., Tibes, R., Weiss, G. J., Borad, M. J., Hann, C. L., Brahmer, J. R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905360 · Cited by 1,109
Self-citation
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma
Sekulic, A., Migden, M. R., Oro, A. E., Dirix, L., Lewis, K. D., Hainsworth, J. D., Solomon, J. A., Yoo, S., Arron, S. T., Friedlander, P. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113713 · Cited by 1,464
Self-citationRealizing the promise of cancer predisposition genes
Rahman, N. (2014) · Nature · doi:10.1038/nature12981 · Cited by 624
Modulating the stem cell niche for tissue regeneration
Lane, S. W., Williams, D. A., & Watt, F. M. (2014) · Nature Biotechnology · doi:10.1038/nbt.2978 · Cited by 615
Unraveling the therapeutic potential of the Hedgehog pathway in cancer
Amakye, D., Jagani, Z., & Dorsch, M. (2013) · Nature Medicine · doi:10.1038/nm.3389 · Cited by 547
Guidelines of care for the management of basal cell carcinoma
Bichakjian, C., Armstrong, A., Baum, C., Bordeaux, J. S., Brown, M., Busam, K. J., Eisen, D. B., Iyengar, V., Lober, C., Margolis, D. J., et al. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.10.006 · Cited by 499
Robinson, G. W., Orr, B. A., Wu, G., Gururangan, S., Lin, T., Qaddoumi, I., Packer, R. J., Goldman, S., Prados, M. D., Desjardins, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.1591 · Cited by 448
Ellis, L. M., Bernstein, D. S., Voest, E. E., Berlin, J. D., Sargent, D., Cortazar, P., Garrett-Mayer, E., Herbst, R. S., Lilenbaum, R. C., Sima, C., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.8009 · Cited by 442
Smoothened Variants Explain the Majority of Drug Resistance in Basal Cell Carcinoma
Atwood, S. X., Sarin, K. Y., Whitson, R. J., Li, J. R., Kim, G., Rezaee, M., Ally, M. S., Kim, J., Yao, C., Chang, A. L. S., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.02.002 · Cited by 404
Self-citationHedgehog Signaling: From Basic Biology to Cancer Therapy
Wu, F., Zhang, Y., Sun, B., McMahon, A. P., & Wang, Y. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.02.010 · Cited by 302
Epidemiology of basal cell carcinoma: scholarly review
Verkouteren, J. A. C., Ramdas, K. H. R., Wakkee, M., & Nijsten, T. (2017) · British Journal of Dermatology · doi:10.1111/bjd.15321 · Cited by 298
Kim, D. J., Kim, J., Spaunhurst, K., Montoya, J., Khodosh, R., Chandra, K., Fu, T., Gilliam, A., Molgo, M., Beachy, P. A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.9525 · Cited by 289
Self-citationHedgehog Partial Agonism Drives Warburg-like Metabolism in Muscle and Brown Fat
Teperino, R., Amann, S., Bayer, M., McGee, S. L., Loipetzberger, A., Connor, T., Jaeger, C., Kammerer, B., Winter, L., Wiche, G., et al. (2012) · Cell · doi:10.1016/j.cell.2012.09.021 · Cited by 283
Basal Cell Skin Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology
Bichakjian, C. K., Olencki, T., Aasi, S. Z., Alam, M., Andersen, J. S., Berg, D., Bowen, G. M., Cheney, R. T., Daniels, G. A., Glass, L. F., et al. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0065 · Cited by 275
Hedgehog pathway inhibitors promote adaptive immune responses in basal cell carcinoma
Otsuka, A., Dreier, J., Cheng, P. F., Nägeli, M., Lehmann, H., Felderer, L., Frew, I. J., Matsushita, S., Levesque, M. P., & Dummer, R. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2110 · Cited by 106
“Clin Cancer Res; 21(6) March 15, 2015 Clinical Cancer Research 1294 Otsuka et al.”
BackgroundInfluentialThe SHH/GLI signaling pathway: a therapeutic target for medulloblastoma
Lospinoso Severini, L., Ghirga, F., Bufalieri, F., Quaglio, D., Infante, P., & Di Marcotullio, L. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1823967 · Cited by 61
Repurposing antifungal drugs for cancer therapy
Weng, N., Zhang, Z., Tan, Y., Zhang, X., Wei, X., & Zhu, Q. (2023) · Journal of Advanced Research · doi:10.1016/j.jare.2022.08.018 · Cited by 60
Maytin, E. V., Kaw, U., Ilyas, M., Mack, J. A., & Hu, B. (2018) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2018.02.009 · Cited by 55
Yoon, J., Apicelli, A. J., & Pavlopoulos, T. V. (2018) · JAAD Case Reports · doi:10.1016/j.jdcr.2017.11.001 · Cited by 32
“It inhibits a transmembrane protein known as smoothened (SMO),(3) which in turn down regulates the expression of Gli genes that are responsible for promoting tumorigenesis.(4) Sonidegib, which targets the same SMO protein, was the second to be approved by the US Food and Drug Administration (FDA) for patients in 2015.”
Background
Metadata
- Authors
- Tang, J. Y., Mackay-Wiggan, J. M., Aszterbaum, M., Yauch, R. L., Lindgren, J., Chang, K., Coppola, C., Chanana, A. M., Marji, J., Bickers, D. R., & Epstein, E. H.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-06-07
- Volume
- 366
- Issue
- 23
- Pages
- 2180-2188
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2031377991
- Cited by
- 547
- References
- 25
- FWCI
- 27.07
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.